NCT05781048View on ClinicalTrials.gov

A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

HRS-6209

HRS-6209

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT05781048 - A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter